New approaches to hematopoietic cell transplantation in oncology

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1437-1466

  Reiss, Ulrike ^a   Bolotin, Ellen ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASPARAGINASE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; ETOPOSIDE; FLUDARABINE; IMATINIB; MAFOSFAMIDE; MELPHALAN; STEROID; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR VACCINE; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; DRUG TOLERANCE; EWING SARCOMA; GENE THERAPY; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; LEUKEMIA REMISSION; MEDULLOBLASTOMA; MYELOID LEUKEMIA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; RADIATION DOSE; REVIEW; RHABDOMYOSARCOMA; TREATMENT FAILURE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; TRANSPLANTATION CONDITIONING;

EID: 0036974034     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00094-9     Document Type: Review

References (272)

1. Andrews RG, Takahashi M, Segal GM, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986;68:1030-5
2. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157-65
3. Gunji Y, Nakamura M, Osawa H, et al. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells. Blood 1993;82:3283-9
4. Bandarenko N, Sims LC, Brecher ME. Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields. Transfusion 1997;37:1218-20
5. Brecher ME, Sims L, Schmitz J, et al. North American Multicenter Study on flow cytometric enumeration of CD34+ hematopoietic stem cells. J Hematother 1996;5:227-36
6. Sims LC, Brecher ME, Gertis K, et al. Enumeration of CD34-positive stem cells: evaluation and comparison of three methods. J Hematother 1997;6:213-26
7. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26
8. Metcalf D. Clinical applications of the agar culture technique for haemopoietic cells. Rev Eur Etud Clin Biol 1971;16:855-9
9. Lewis ID, Rawling T, Dyson PG, et al. Standardization of the CFU-GM assay using hematopoietic growth factors. J Hematother 1996;5:625-30
10. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970;36:507-15
11. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997;20:1033-7
12. Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin Transplant 2001;15:317-23
13. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001;98:3186-91
14. Moss TJ, Cairo M, Santana VM, et al. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 1994;83:3085-9
15. Moss TJ, Sanders DG, Lasky LC, et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990;76:1879-83
16. Horowitz MM, Loberiza FR, Bredeson CN, et al. Transplant registries: guiding clinical decisions and improving outcomes. Oncology (Huntingt) 2001;15:649-66
17. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001;27:689-92
18. Bornhauser M, Theuser C, Soucek S, et al. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Haematologica 2000;85:839-47
19. Dreger P, Viehmann K, Steinmann J, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 1995;23:147-54
20. Harada M, Nagafuji K, Fujisaki T, et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. J Hematother 1996;5:63-71
21. Martin C, Torres A, Leon A, et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Bone Marrow Transplant 1998;21:375-82
22. Pan L, Bressler S, Cooke KR, et al. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors. Biol Blood Marrow Transplant 1996;2:126-33
23. Rambaldi A, Viero P, Bassan R, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. Leukemia 1996;10:860-5
24. de Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001;41:190-5
25. Gianni AM, Siena S, Bregni M. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1991;19:147-8
26. Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71:723-7
27. Korbling M, Dorken B, Ho AD, et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67: 529-32
28. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2:580-5
29. Halle P, Kanold J, Rapatel C, et al. Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs. 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000;4:285-8
30. Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992;79:3036-44
31. Lasky LC, Bostrom B, Smith J, et al. Clinical collection and use of peripheral blood stem cells in pediatric patients. Transplantation 1989;47:613-6
32. Kanold J, Halle P, Rapatel C, et al. Safe and efficient peripheral blood stem cell collection in the smallest of children. Ther Apher 1998;2:49-57
33. Kawano Y, Takaue Y, Watanabe T, et al. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. Cancer Res 1999;59:3321-4
34. Kawano Y, Watanabe T, Takaue Y. Mobilization/harvest and transplantation with blood stem cells, manipulated or unmanipulated. Pediatr Transplant 1999;3:65-71
35. Urban C, Schwinger W, Benesch M, et al. Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG. Med Pediatr Oncol 1997;29:115-20
36. Elias AD, Ayash L, Tepler I, et al. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother 1993;2:377-82
37. Gazitt Y, Callander N, Freytes CO, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in nonHodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000;9:737-48
38. Hohaus S, Martin H, Wassmann B, et al. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998;22:625-30
39. Rosenfeld CS, Bolwell B, LeFever A, et al. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone Marrow Transplant 1996;17:179-83
40. Eto T, Takamatsu Y, Harada M, et al. Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells. Bone Marrow Transplant 1994; 13:125-9
41. Horsfall MJ, Hui CH, To LB, et al. Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay. Br J Haematol 2000;109:751-8
42. Lee V, Li CK, Shing MM, et al. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplant 2000;25:931-5
43. Ravagnani F, Bregni M, Siena S, et al. Role of recombinant human granulocyte-macrophage colony stimulating factor for large scale collection of peripheral blood stem cells for autologous transplantation. Haematologica 1990;75(Suppl 1):22-5
44. Shen V, Woodbury C, Killen R, et al. Collection and use of peripheral blood stem cells in young children with refractory solid tumors. Bone Marrow Transplant 1997;19:197-204
45. Goldman SC, Bracho F, Davenport V, et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 2001;23:300-5
46. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-7
47. Brisse H, Edeline V, Michon J, et al. Current strategy for the imaging of neuroblastoma. J Radiol 2001;82:447-54
48. Rill DR, Buschle M, Foreman NK, et al. Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther 1992;3:129-36
49. Kasparu H, Krieger O, Girschikofsky M, et al. Factors influencing the timing of peripheral blood stem cell collection (PBSC). Transfus Sci 1996;17:595-600
50. Olivieri A, Offidani M, Ciniero L, et al. PBSC collection after high dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors. Int J Artif Organs 1993;16(Suppl 5):57-63
51. Hartmann O, Benhamou E, Beaujean F, et al. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987;5:1205-11
52. Reynolds CP, Seeger RC, Vo DD, et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46:5882-6
53. Donovan J, Temel J, Zuckerman A, et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000;35:677-82
54. Handgretinger R, Greil J, Schurmann U, et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997;6:235-42
55. Lebkowski JS, Schain LR, Okrongly D, et al. Rapid isolation of human CD34 hematopoietic stem cells - purging of human tumor cells. Transplantation 1992;53:1011-9
56. Lopez M, Beaujean F. Positive selection of autologous peripheral blood stem cells. Bailliere's Best Pract Res Clin Haematol 1999;12:71-86
57. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-5
58. Tchirkov A, Kanold J, Giollant M, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998;30:228-32
59. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22:11-4
60. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001;8:146-54
61. Kelly P, Kurtzberg J, Vichinsky E, et al. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr 1997;130:695-703
62. Rocha V, Chastang C, Souillet G, et al. Related cord blood transplants: the Eurocord experience from 78. transplants. Eurocord Transplant group. Bone Marrow Transplant 1998;21(Suppl 3):S59-62
63. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-71
64. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77
65. Wagner JE, Kurtzberg J. Banking and transplantation of unrelated donor umbilical cord blood: status of the National Heart, Lung, and Blood Institute-sponsored trial. Transfusion 1998; 38:807-9
66. Kobayashi H, Man S, Graham CH, et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 1993;90:3294-8
67. Teicher BA, Ara G, Keyes SR, et al. Acute in vivo resistance in high-dose therapy. Clin Cancer Res 1998;4:483-91
68. Teicher BA, Holden SA, Eder JP, et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989;49:5994-8
69. Teicher BA, Northey D, Yuan J, et al. High-dose therapy/stem cell support: comparison of mice and humans. Int J Cancer 1996;65:695-9
70. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796-803
71. Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999;24:1157-9
72. Eder JP, Elias A, Shea TC, et al. A phase I - II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990;8:1239-45
73. Hawkins D, Barnett T, Bensinger W, et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000;34:328-37
74. Kletzel M, Abella EM, Sandler ES, et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol Oncol 1998;20:49-54
75. Lilley ER, Rosenberg MC, Elion GB, et al. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res 1990;50:284-7
76. Ozkaynak MF, Matthay K, Cairo M, et al. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol 1998;16:937-44
77. Shaw PJ, Pinkerton CR, Yaniv I. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Bone Marrow Transplant 1996;18:1043-7
78. Worth L, Tran H, Petropoulos D, et al. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant 1999;24:947-52
79. Appelbaum FR, Badger CC, Bernstein ID, et al. Is there a better way to deliver total body irradiation? Bone Marrow Transplant 1992;10:77-81
80. Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 1984;10:957-64
81. Aristei C, Alessandro M, Santucci A, et al. Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation. Bone Marrow Transplant 2002;29:503-7
82. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002;8:139-44
83. Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999;94:3960-2
84. van Kempen-Harteveld ML, Struikmans H, Kal HB, et al. Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment. Int J Radiat Oncol Biol Phys 2002;52:1375-80
85. Bakker B, Massa GG, Oostdijk W, et al. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr 2000;159:31-7
86. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000;25:925-30
87. Pawlowska AB, Blazar BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997;20:915-20
88. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002;53:386-9
89. Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long-term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000;85:1060-7
90. Kroger N, Zabelina T, Kruger W, et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001;27:349-54
91. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74
92. von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1995;16:521-7
93. Carpenter PA, Marshall GM, Giri N, et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996;18:489-94
94. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000;111:6-17
95. Slavin S, Nagler A, Aker M, et al. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. Rev Clin Exp Hematol 2001;5:135-46
96. Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001; 7:473-85
97. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9
98. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006
99. Bordigoni P, Vemant J, Souillet G, et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 1989;7:747-53
100. Deconinck E, Cahn JY, Milpied N, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). Bone Marrow Transplant 1997;20:731-5
101. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-26
102. Uderzo C, Valsecchi MG, Balduzzi A, et al. Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1997;96:387-94
103. Barrett AJ, Horowitz MM. Transplants in ALL. Bone Marrow Transplant 1992;10:30-6
104. Barrett AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989;74:862-71
105. Barrett AJ, Horowitz MM, McCarthy DM, et al. Bone marrow transplantation for acute lymphoblastic leukaemia in first and second remission. Bone Marrow Transplant 1989;4(Suppl 1):247-9
106. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-8
107. Bortin MM, Barrett AJ, Horowitz MM, et al. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980s: a report from the IBMTR. The International Bone Marrow Transplant Registry. Leukemia 1992;6:196-7
108. Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000;95:3996-4003
109. Chessells JM, Leiper AD, Richards SM. A second course of treatment for childhood acute lymphoblastic leukaemia: long-term follow-up is needed to assess results. Br J Haematol 1994;86:48-54
110. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90
111. Harrison G, Richards S, Lawson S, et al. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial, MRC Childhood Leukaemia Working Party. Ann Oncol 2000;11:999-1006
112. Herzig RH, Bortin MM, Barrett AJ, et al. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1987;1:786-9
113. Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-8
114. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002;20:405-12
115. Passweg JR, Rowlings PA, Atkinson KA, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998;21:1231-8
116. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998;21:153-8
117. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer 1998;82:1387-95
118. Schroeder H, Garwicz S, Kristinsson J, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995;25:372-8
119. Wheeler KA, Richards SM, Bailey CC, et al. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and X1. Blood 2000;96:2412-8
120. Borgmann A, Hartmann R, Schmid H, et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation, BFM Relapse Study Group. Bone Marrow Transplant 1995;15:515-21
121. Conter V, Arico M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 1998;83:791-9
122. Winick NJ, Smith SD, Shuster J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993;11:271-8
123. Uderzo C, Grazia Zurlo M, Adamoli L, et al. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Associazione Italiana Ematologia ed Oncologia Pediatrica. J Clin Oncol 1990;8:672-7
124. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000;108:531-43
125. Billett AL, Sallan SE. Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging. Am J Pediatr Hematol Oncol 1993;15:162-8
126. Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997;90:2962-8
127. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood 1995;86:3247-56
128. Casper J, Camitta B, Truitt R, et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995;85:2354-63
129. Davies SM, Ramsay NK, Weisdorf DJ. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 1996;17:737-40
130. Davies SM, Wagner JE, Shu XO, et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997;15:557-65
131. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602
132. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999;93:3662-71
133. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340-7
134. Houtenbos I, Bracho F, Davenport V, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno- and chemotherapy (PTIC). Bone Marrow Transplant 2001;27:145-53
135. Juneja HS, Harvey WH, Brasher WK, et al. Successful in vitro purging of leukemic blasts from marrow by cortivazol, a pyrazolosteroid: a preclinical study for autologous transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leukemia 1995;9:1771-8
136. Mehta J, Powles R, Treleaven J, et al. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. Leuk Lymphoma 1997;25:479-86
137. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol 1999;36:2-8
138. Abella E, Ravindranath Y. Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. Curr Oncol Rep 2000;2:529-38
139. Burnett AK, Kell J. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Curr Opin Oncol 2000;12:110-5
140. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001;19:2705-13
141. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA: European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1998;102:1344-53
142. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101:130-40
143. Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98:1714-20
144. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999;104:630-9
145. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62
146. Leung W, Pitts N, Bumette K, et al. Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant 2001;27:717-22
147. Ringden O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1997;19:963-8
148. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397-404
149. Marks DI, Bird JM, Vettenranta K, et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000;6:646-53
150. Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999;17:1545-50
151. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-8
152. Burnett AK, Kell J, Rowntree C. Acute myeloid leukemia: therapeutic indications. Curr Opin Hematol 2000;7:333-8
153. Burnett AK, Kell J, Rowntree C. Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia. Int J Hematol 2000;72:280-4
154. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428-34
155. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1997;20:307-15
156. Lemoli RM, Visani G, Leopardi G, et al. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone Marrow Transplant 1999;23:235-41
157. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997;90:1321-5
158. Miller CB, Rowlings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001;29:1336-46
159. Fauth F, Martin H, Sonnhoff S, et al. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells. Bone Marrow Transplant 2000;25:831-6
160. Motta MR, Mangianti S, Rizzi S, et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Exp Hematol 1997;25:1261-9
161. Atta J, Fauth F, Keyser M, et al. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplant 2000;25:97-104
162. Horikoshi Y, Mimaya J, Amano K, et al. Feasibility study of autologous peripheral blood stem cell transplantation for the treatment of childhood acute myelogenous leukemia. Jpn J Clin Oncol 2000;30:137-45
163. Vellenga E, van Putten WL, Boogaerts MA, et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999;23:1279-82
164. Reiffers J, Labopin M, Sanz M, et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 2000;25:1115-59
165. Dusenbery KE, Steinbuch M, McGlave PB, et al. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience. Int J Radiat Oncol Biol Phys 1996;36:335-43
166. Dusenbery KE, Daniels KA, McClure JS, et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995;31:119-28
167. Tiedemann K, Waters KD, Tauro GP, et al. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993;82:3730-8
168. Nagler A, Finlander R, Or R, et al. The role of thiotepa in autologous bone marrow transplantation for acute leukemia. Leuk Res 1998;22:991-5
169. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237-47
170. Ruffner KL, Matthews DC. Current uses of monoclonal antibodies in the treatment of acute leukemia. Semin Oncol 2000;27:531-9
171. Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000;11:91-8
172. Cortes JE, Kantarjian HM, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999;85:1506-13
173. Goldberg SL, Pecora AL, Rosenbluth RJ, et al. Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft- versus-leukemia and graft-versus-host effects with cytokines. Bone Marrow Transplant 2000;26:353-5
174. Kloosterman TC, Martens AC, Osterwalder B, et al. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML. Bone Marrow Transplant 1994;14:965-73
175. Maraninchi D, Vey N, Viens P, et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma 1998;31:343-9
176. Margolin K, Forman SJ. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Cancer J Sci Am 2000;6(Suppl 1):S33-8
177. Meloni G, Foa R, Tosti S, et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 1992;6:780-5
178. Messina C, Zambello R, Rossetti F, et al. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transplant 1996; 17:729-35
179. Robinson N, Benyunes MC, Thompson JA, et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997;19:435-42
180. Sievers EL, Lange BJ, Sondel PM, et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000;6(Suppl 1):S39-44
181. Miller JS, Panoskaltsis-Mortari A, Curtsinger JR, Blazar BR. Flt3 ligand safely increases dendritic cells after autologous transplantation which may be useful to correct the impaired immune response to neo-antigens after autologous transplant. Blood Program and abstracts of the 43rd Annual Meeting of the American Society of Hematology. Orlando (FL), December 7-11, 2001; Abstract 3569
182. Hale GA, Tong X, Benaim E, et al. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant 2001;27:155-62
183. Tomas F, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996;17:979-84
184. Webb DK, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999;13:25-31
185. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994;84:3603-12
186. Higano CS, Brixey M, Bryant EM, et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990;50:175-7
187. Camba L, Bemardi M, Pescarollo A. Complete haematological response with granulocyte colony stimulating factor (G-CSF) and hydroxyurea in relapsed acute myeloid leukaemia (AML) of the elderly. Haematologica 2001;86:E21
188. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993;329:757-61
189. Shulman LN, Tarbell NJ, Storen E, et al. Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission. Int J Radiat Oncol Biol Phys 1998;42:1113-7
190. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5
191. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998; 74:321-9
192. Michallet M, Thomas X, Vemant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000;26:1157-63
193. Porter DL, Collins Jr RH, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-21
194. Ringden O, Labopin M, Gorin NC, et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000;25:1053-8
195. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-16
196. The Italian Cooperative Study Group on Chronic Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998;92:1541-8
197. Reiter A, Hochhaus A, Berger U, et al. AraC-based pharmacotherapy of chronic myeloid leukaemia. Expert Opin Pharmacother 2001;2:1129-35
198. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96:3195-9
199. Applebaum FR, Clift R, Buckner CD, et al. Allogeneic marrow transplantation for chronic myeloid leukemia. Med Oncol 1994;11:69-74
200. Sharathkumar A, Thornley I, Saunders EF, et al. Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. J Pediatr Hematol Oncol 2002;24:215-9
201. Gamis AS, Haake R, McGlave P, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993;11:834-8
202. Vormoor J, Boos J, Stahnke K, et al. Therapy of childhood acute myelogenous leukemias. Ann Hematol 1996;73:11-24
203. Sanders JE, Buckner CD, Thomas ED, et al. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood 1988;71:1144-6
204. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002;116:716-24
205. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002;20:434-40
206. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73
207. Pole JG, Casper J, Elfenbein G, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:152-8
208. Pinkerton CR. ENSG 1-randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant 1991;7:112-3
209. Ohnuma N, Takahashi H, Kaneko M, et al. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 1995;24:181-7
210. Shuster JJ, Cantor AB, McWilliams N, et al. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991;9:1045-9
211. Evans AE, August CS, Kamani N, et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. Med Pediatr Oncol 1994;23:323-7
212. Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994;14:37-46
213. Matthay KK, Seeger RC, Reynolds CP, et al. Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Prog Clin Biol Res 1994;385:301-7
214. Ladenstein R, Philip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 1997;9:55-69
215. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-76
216. Ladenstein R, Pearce R, Hartmann O, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997;90:2921-30
217. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-75
218. Graham-Pole J, Gee A, Emerson S, et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood 1991;78:1607-14
219. Kushner BH, Cheung NK, Kramer K, et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001;28:551-6
220. Park JR, Slattery J, Gooley T, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol 2000;35:719-23
221. Hoefnagel CA, Rutgers M, Buitenhuis CK, et al. A comparison of targeting of neuroblastoma with mIBG and anti-L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 2001;28:359-68
222. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001;27:571-4
223. Manzke O, Russello O, Leenen C, et al. Immunotherapeutic strategies in neuroblastoma: anti-tumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Med Pediatr Oncol 2001;36:185-9
224. Cheung NK. Monoclonal antibody-based therapy for neuroblastoma. Curr Oncol Rep 2000; 2:547-53
225. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000;18:4077-85
226. Andre M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999;17:222-9
227. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4
228. Williams CD, Goldstone AH, Pearce R, et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993;11:2243-9
229. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-22
230. Baker KS, Gordon BG, Gross TG, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17:825-31
231. Clarke CA, Glaser SL, Prehn AW. Age-specific survival after Hodgkin's disease in a population-based cohort (United States). Cancer Causes Control 2001;12:803-12
232. Hawkins RE, Russell SJ, Marcus R, et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC No. 92/33. Protocol No. PHI/027. Hum Gene Ther 1997;8:1287-99
233. Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1998;25:503-17
234. Moody AM, Pratt J, Hudson GV, et al. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Clin Oncol 2001;13:262-8
235. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000;39:509-19
236. Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001;19:727-35
237. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001;19:4314-21
238. Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993;11:1024-32
239. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 20:369-74
240. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-8
241. Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14:1291-6
242. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and 1-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001;19:2390-6
243. Delain M, Cartron G, Bout M, et al. Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Leuk Lymphoma 1999;34:305-13
244. Carella AM, Prencipe E, Pungolino E, et al. Twelve years' experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma 1996;21:63-70
245. Fitoussi O, Simon D, Brice P, et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999;24:747-55
246. Stewart DA, Guo D, Gluck S, et al. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000;26:383-8
247. Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89:3951-9
248. Appelbaum FR, Deisseroth AB, Graw Jr RG, et al. Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978;41:1059-63
249. Hartmann O, Pein F, Beaujean F, et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol 1984;2:979-85
250. Philip T, Biron P, Maraninchi D, et al. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma. Br J Haematol 1985; 60:599-609
251. O'Leary M, Ramsay NK, Nesbit Jr ME, et al. Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study. Am J Med 1983;74:497-501
252. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451-8
253. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000;1:46-54
254. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive nonHodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-13
255. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20(10):2472-9
256. Santini G, Coser P, Congiu AM, et al. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Cooperative Study Group. Haematologica 2000;85:160-6
257. Chauvin F, Ladenstein R, Lasset C, et al. European Bone Marrow Registry in solid tumors: 7 years of experience. Bone Marrow Transplant 1991;7(Suppl 2):157
258. Zoubek A, Holzinger B, Mann G, et al. High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor. J Pediatr Hematol Oncol 1994;11:613-23
259. Miser JS, Kinsella TJ, Triche TJ, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 1988;6:484-90
260. D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989;64:349-60
261. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989; 7:638-47
262. Perentesis J, Katsanis E, DeFor T, et al. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 1999;24:609-15
263. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998;16:3295-301
264. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-31
265. Gamis A, Gordon B, Watanabe M, Laurence K, Simon S. High dose chemotherapy with stem cell rescue for children with relapsed and high risk solid tumors; preliminary survival analysis. Blood 2001;98:692a
266. Mandanas RA, Saez RA, Epstein RB, et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998;21:569-76
267. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables [see comments]. J Clin Oncol 1996; 14:2638-45
268. Hara I, Yamada Y, Miyake H, et al. Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors. Anticancer Drugs 1999;10:711-8
269. Ciordia R, Supko J, Gatineau M, et al. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr Oncol Rep 2000;2:445-53
270. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 1998;16:222-8
271. Mahoney Jr DH, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996;14:382-8
272. Graham ML, Herndon II JE, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814-23